The trial included 107 patients with FGFR2 fusions/rearrangements, 20 with other FGF/FGFR aberrations, and 18 CCA patients without alterations; following a median follow-up of 17.8 months, ORR was observed in 35.5% (38/107) of patients harbouring FGFR2 gene fusions and/or rearrangements, with three cases of complete response and a median duration of treatment of 7.2 months. This evidence concerns the gene FGFR2 and cholangiocarcinoma.